Cytokinetics secures Canadian MYQORZO approval after 24-week trial
Cytokinetics (NASDAQ:CYTK) received Health Canada approval for MYQORZO to treat adults with NYHA class II–III symptomatic obstructive hypertrophic cardiomyopathy, supported by 24-week trial results.










